K Number
K130243
Device Name
ILAB ULTRASOUND IMAGING SYSTEM
Date Cleared
2013-03-01

(29 days)

Product Code
Regulation Number
892.1560
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The iLab™ Ultrasound Imaging System is intended for ultrasound examinations of intravascular pathology. Intravascular ultrasound is indicated in patients who are candidates for transluminal interventional procedures such as angioplasty and atherectomy.
Device Description
The iLab Ultrasound Imaging System is designed for real time viewing of intravascular anatomies and is intended to be a basic diagnostic tool for imaging and evaluation of patients who are candidates for transluminal procedures.
More Information

Not Found

No
The summary does not mention AI, ML, deep learning, or any related terms, nor does it describe features or performance metrics typically associated with AI/ML-powered devices. The description focuses on basic real-time imaging and diagnostic tools.

No
The device is described as a "basic diagnostic tool for imaging and evaluation of patients" and its intended use is for "ultrasound examinations of intravascular pathology." These functions are diagnostic, not therapeutic.

Yes
The "Intended Use / Indications for Use" section states, "The iLab™ Ultrasound Imaging System is intended for ultrasound examinations of intravascular pathology." Additionally, the "Device Description" section explicitly states, "The iLab Ultrasound Imaging System is intended to be a basic diagnostic tool for imaging and evaluation of patients who are candidates for transluminal procedures."

No

The device description explicitly refers to an "Ultrasound Imaging System," which inherently includes hardware components for image acquisition (ultrasound transducer, processing unit, etc.). The summary also mentions "Electrical Safety testing," which is typically performed on hardware.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, tissue) to provide information about a person's health.
  • Device Function: The iLab™ Ultrasound Imaging System is used for intravascular ultrasound examinations. This involves using ultrasound technology within the body to visualize anatomical structures. It does not analyze specimens taken from the body.
  • Intended Use: The intended use clearly states it's for "ultrasound examinations of intravascular pathology" and is a "basic diagnostic tool for imaging and evaluation of patients". This describes an imaging device used directly on the patient, not a device that analyzes samples in a lab setting.

Therefore, based on the provided information, the iLab™ Ultrasound Imaging System is an in vivo diagnostic imaging device, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The iLab™ Ultrasound Imaging System is intended for ultrasound examinations of intravascular pathology. Intravascular ultrasound is indicated in patients who are candidates for transluminal interventional procedures such as angioplasty and atherectomy.

Product codes (comma separated list FDA assigned to the subject device)

IYO, ITX

Device Description

The iLab Ultrasound Imaging System is designed for real time viewing of intravascular anatomies and is intended to be a basic diagnostic tool for imaging and evaluation of patients who are candidates for transluminal procedures.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Ultrasound

Anatomical Site

intravascular pathologies

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non-clinical data, including functional/performance testing, interoperability testing, and Electrical Safety testing has been evaluated as detailed in Section VI of this premarket notification. Design verification testing demonstrates that the modified device meets the acceptance criteria.

The modified iLab Ultrasound Imaging System did not require clinical studies to support substantial equivalence.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K123535

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 892.1560 Ultrasonic pulsed echo imaging system.

(a)
Identification. An ultrasonic pulsed echo imaging system is a device intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). A biopsy needle guide kit intended for use with an ultrasonic pulsed echo imaging system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

0

K130243

Page 1 of 2

Boston
Scientific

MAR 1 2013

Boston Scientific Corporation iLab Ultrasound Imaging System Special Premarket Notification January 30, 2013

510(k) Summary of Safety and Effectiveness Boston Scientific Corporation iLab™ Ultrasound Imaging System

General Information

Manufacturer:

Establishment Registration Number:

Contact Person:

Boston Scientific Corporation 47215 Lakeview Boulevard Fremont, CA 94538

2939204

Lori R. Smith Sr. Regulatory Affairs Specialist Tel: (510) 624-1698 Fax: (510) 624-2569 lori.smith@bsci.com

Date Prepared:

Device Description Classification Name(s): January 30, 2013

Class II Ultrasonic Pulsed Echo Imaging System 21 CFR Part 892.1560 (90IYO) Transducer, Ultrasonic, Diagnostic 21 CFR Part 892.1570 (90ITX)

Trade Name:

Generic/Common Name:

iLab™ Ultrasound Imaging System

Ultrasound Diagnostic Imaging System Ultrasonic Pulsed Echo Imaging System (90IYO) Transducer, Ultrasonic, Diagnostic (90ITX)

Predicate Devices

iLab Ultrasound Imaging System

K123535

Intended Uses/Indications for Use

The iLab™ Ultrasound Imaging System is intended for ultrasound examinations of intravascular pathology. Intravascular ultrasound is indicated in patients who are

1

Boston Scientific Corporation iLab Ultrasound Imaging System Special Premarket Notification January 30, 2013

candidates for transluminal interventional procedures such as angioplasty and atherectomy.

Product Description

The iLab Ultrasound Imaging System is designed for real time viewing of intravascular anatomies and is intended to be a basic diagnostic tool for imaging and evaluation of patients who are candidates for transluminal procedures.

Technology

The modified iLab Ultrasound Imaging System employs the same fundamental scientific technology as its predicate device.

Determination of Substantial Equivalence

Summary of Non-Clinical Tests:

Non-clinical data, including functional/performance testing, interoperability testing, and Electrical Safety testing has been evaluated as detailed in Section VI of this premarket notification. Design verification testing demonstrates that the modified device meets the acceptance criteria.

Summary of Clinical Tests:

The modified iLab Ultrasound Imaging System did not require clinical studies to support substantial equivalence.

Conclusion

The modifications in performance specifications and labeling for the iLab™ Ultrasound Imaging System are not substantial changes or modifications that would significantly affect the safety or efficacy of the device. The proposed iLab Ultrasound Imaging System, which introduces the new MDU5 PLUS motordrive, is essentially equivalent in technology, principle of operation, packaging, and indications for use as the iLab Ultrasound Imaging System previously cleared in K123535.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" arranged in a circular fashion around the symbol. The text is in all caps and is evenly spaced around the circle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 1, 2013

Lori R. Smith Senior Regulatory Affairs Specialist Boston Scientific Corp. 47215 Lakeview Boulevard FREMONT CA 94538

Re: K130243

Trade/Device Name: iLab Ultrasound Imaging System Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo imaging system Regulatory Class: II Product Code: IYO, ITX Dated: January 30, 2013 Received: February 4, 2013

Dear Lori R. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

3

Page 2- Lori R. Smith

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Smith

for

Janine Morris Director, Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

4

Boston Scientific Corporation iLab Ultrasound Imaging System Special Premarket Notification January 30, 2013

Indications for Use Statement

510(k) Number (if known):

Device Name: iLab™ Ultrasound Imaging System

Indications for Use:

The iLab™ Ultrasound Imaging System is intended for ultrasound examinations of intravascular pathology. Intravascular ultrasound is indicated in patients who are candidates for transluminal interventional procedures such as angioplasty and atherectomy.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Sm

(Division Sign Off) Division of Radiological Health Office of In Vitro Diagnostic and Radiological Health

K130243 510(k)

Page 1 of

Page 31 of 395